SURG vs GLIBA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

SURG

40.3
AI Score
VS
GLIBA Wins

GLIBA

49.1
AI Score

Investment Advisor Scores

SURG

40score
Recommendation
HOLD

GLIBA

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric SURG GLIBA Winner
Revenue 15.98M 256.00M GLIBA
Net Income -12.05M 18.00M GLIBA
Net Margin -75.4% 7.0% GLIBA
Operating Income -11.20M 30.00M GLIBA
ROE 50.6% 1.1% SURG
ROA -126.8% 0.6% GLIBA
Total Assets 9.50M 3.25B GLIBA
Cash 1.99M 435.00M GLIBA
Current Ratio 0.27 3.31 GLIBA

Relative Price Performance (Last 90 Days)

SURG 1M: -19.6% · 3M: -40.7% GLIBA 1M: +5.9% · 3M: -26.9%

Current Technical Phase

SURG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.4 · Price: $0.32

GLIBA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 59

RSI (14): 59.1 · Price: $24.31

Fundamentals Snapshot

Metric SURG GLIBA
Market Cap
Forward P/E 4.5 6.1
Trailing P/E
Revenue (TTM)
Revenue Growth 0.5% 0.0%
Gross Margin -0.2% 0.5%
Operating Margin -0.7% 0.1%
EPS -1.93 -8.27
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, GLIBA is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.